Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Interleukin-6: minor player or starring role in the development of hormone-refractory prostate cancer?

× No keyword cloud information.

16 in total

Review 1. Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives.

Authors: Nagalakshmi Nadiminty; Allen C Gao
Journal: World J Urol Date: 2011-10-19 Impact factor: 4.226

2. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer.

Authors: Tanya B Dorff; Bryan Goldman; Jacek K Pinski; Philip C Mack; Primo N Lara; Peter J Van Veldhuizen; David I Quinn; Nicholas J Vogelzang; Ian M Thompson; Maha H A Hussain
Journal: Clin Cancer Res Date: 2010-05-18 Impact factor: 12.531

3. LNCaP prostate cancer cells with autocrine interleukin-6 expression are resistant to IL-6-induced neuroendocrine differentiation due to increased expression of suppressors of cytokine signaling.

Authors: Dongxia Ge; Allen C Gao; Qiuyang Zhang; Sen Liu; Yun Xue; Zongbing You
Journal: Prostate Date: 2011-12-27 Impact factor: 4.104

Review 4. Paraneoplastic syndromes in prostate cancer.

Authors: Matthew K Hong; Jennifer Kong; Benjamin Namdarian; Anthony Longano; Jeremy Grummet; Christopher M Hovens; Anthony J Costello; Niall M Corcoran
Journal: Nat Rev Urol Date: 2010-12 Impact factor: 14.432

5. Consistent interactions between tumor cell IL-6 and macrophage TNF-α enhance the growth of human prostate cancer cells in the bone of nude mouse.

Authors: Seung Wook Kim; Jang Seong Kim; John Papadopoulos; Hyun Jin Choi; Junqin He; Marva Maya; Robert R Langley; Dominic Fan; Isaiah J Fidler; Sun-Jin Kim
Journal: Int Immunopharmacol Date: 2011-01-18 Impact factor: 4.932

Review 6. Understanding and targeting osteoclastic activity in prostate cancer bone metastases.

Authors: J L Sottnik; E T Keller
Journal: Curr Mol Med Date: 2013-05 Impact factor: 2.222

7. Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality.

Authors: Jennifer Rider Stark; Haojie Li; Peter Kraft; Tobias Kurth; Edward L Giovannucci; Meir J Stampfer; Jing Ma; Lorelei A Mucci
Journal: Int J Cancer Date: 2009-06-01 Impact factor: 7.396

8. aPKClambda/iota promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6.

Authors: Hitoshi Ishiguro; Kazunori Akimoto; Yoji Nagashima; Yasuyuki Kojima; Takeshi Sasaki; Yukari Ishiguro-Imagawa; Noboru Nakaigawa; Shigeo Ohno; Yoshinobu Kubota; Hiroji Uemura
Journal: Proc Natl Acad Sci U S A Date: 2009-09-02 Impact factor: 11.205

9. Interleukin-17 promotes development of castration-resistant prostate cancer potentially through creating an immunotolerant and pro-angiogenic tumor microenvironment.

Authors: Qiuyang Zhang; Sen Liu; Qingsong Zhang; Zhenggang Xiong; Alun R Wang; Leann Myers; Jonathan Melamed; Wendell W Tang; Zongbing You
Journal: Prostate Date: 2014-04-01 Impact factor: 4.104

10. Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells.

Authors: T Terakawa; H Miyake; J Furukawa; S L Ettinger; M E Gleave; M Fujisawa
Journal: Br J Cancer Date: 2009-10-20 Impact factor: 7.640